All In MedTech

Device Trial Radar · NCT07951723

Enhanced Expiratory Rebreathing Space Therapy for Complex Sleep Apnea in Patients With Cardiovascular Disease

Identification and Management of Complex Sleep Apnea in Patients With Cardiovascular Disease

Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

40

Planned (sponsor's estimate)

Start

Dec 1, 2026

Primary completion

Nov 15, 2027

Study completion Nov 30, 2027

Sponsor

Lead sponsor
Chinese Pulmonary Vascular Disease Research GroupAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Nov 20, 2026

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated device
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study aims to evaluate the effectiveness and safety of enhanced expiratory rebreathing space (EERS) therapy compared with conventional automatic positive airway pressure (APAP) therapy in patients with cardiovascular disease and complex sleep apnea (CompSA). This is a prospective, single-center, randomized controlled trial involving 40 participants aged 18-75 years. Eligible participants will be randomly assigned to either the EERS group or the conventional APAP group in a 1:1 ratio. Participants in the EERS group will receive individualized EERS therapy guided by overnight sleep monitoring, while those in the control group will receive conventional APAP therapy. Each participant will be followed for five weeks, including a one-week screening period, a two-week treatment period, and a two-week follow-up period. The primary outcome is the apnea-hypopnea index (AHI), which measures the number of breathing interruptions per hour of sleep, assessed after two weeks of treatment. Additional outcomes include other sleep-related breathing measures, cardiovascular health indicators, treatment adherence, comfort, and adverse events. The findings may help determine whether EERS therapy is an effective and safe treatment option for complex sleep apnea in patients with cardiovascular disease.

Conditions

  • Complex Sleep Apnea
  • Cardiovascular Diseases (CVD)

Interventions

  • Enhanced Expiratory Rebreathing Space (EERS) TherapyDevice

    Participants will undergo individualized manual continuous positive airway pressure (CPAP) titration under overnight polysomnographic (PSG) monitoring. An enhanced expiratory rebreathing space (EERS) device will be connected between the patient interface and a single-level CPAP device to increase expiratory carbon dioxide rebreathing and stabilize respiratory control. End-tidal carbon dioxide (EtCO₂) will be monitored throughout titration. CPAP pressure will initially be set at 4-6 cmH₂O and manually adjusted by trained sleep technicians in increments of 1-2 cmH₂O to eliminate obstructive respiratory events. The lowest effective pressure will be selected for subsequent treatment. Participants will then receive home-based CPAP therapy combined with EERS for two weeks.

  • Automatic Positive Airway Pressure (APAP) TherapyDevice

    Participants will undergo conventional automatic positive airway pressure (APAP) titration during overnight sleep monitoring using a single-level noninvasive positive airway pressure device and a nasal or oronasal mask. The initial pressure range will be set at 4-18 cmH₂O. The device will automatically adjust airway pressure in response to obstructive respiratory events, including apnea, hypopnea, snoring, and airflow limitation. Sleep technicians will monitor respiratory signals, oxygen saturation, mask leakage, and treatment tolerance. Individualized treatment settings will be determined based on overnight titration results, followed by two weeks of home-based positive airway pressure therapy.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Apnea-Hypopnea Index (AHI) After Two Weeks of TreatmentTime frame: 2 weeks after initiation of treatment

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.